Does the media refer more to RARE or MDXG?

In the previous week, Ultragenyx Pharmaceutical had 15 more articles in the media than MiMedx Group. MarketBeat recorded 21 mentions for Ultragenyx Pharmaceutical and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.15 beat Ultragenyx Pharmaceutical's score of 1.07 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 10 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDXG or NKTR?

In the previous week, Nektar Therapeutics had 3 more articles in the media than MiMedx Group. MarketBeat recorded 9 mentions for Nektar Therapeutics and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.15 beat Nektar Therapeutics' score of 0.65 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KOD or MDXG?

In the previous week, Kodiak Sciences had 3 more articles in the media than MiMedx Group. MarketBeat recorded 9 mentions for Kodiak Sciences and 6 mentions for MiMedx Group. Kodiak Sciences' average media sentiment score of 1.29 beat MiMedx Group's score of 1.15 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCRX or MDXG?

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than MiMedx Group. MarketBeat recorded 12 mentions for BioCryst Pharmaceuticals and 6 mentions for MiMedx Group. BioCryst Pharmaceuticals' average media sentiment score of 1.39 beat MiMedx Group's score of 1.15 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MDXG or PGEN?

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.57 $48.58M $0.04 112.50 Precigen $9.68M 255.97 -$250.64M -$1.04 N/A

Is MDXG or PGEN more profitable?

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group 1.76% 12.09% 9.22% Precigen -183.98% 423.75% 84.39%

Does the media prefer MDXG or PGEN?

In the previous week, Precigen had 10 more articles in the media than MiMedx Group. MarketBeat recorded 16 mentions for Precigen and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.15 beat Precigen's score of 0.65 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MiMedx Group (MDXG) Competitors

$4.50 -0.01 (-0.22%)

As of 04:00 PM Eastern

Compare

MDXG vs. RARE, NKTR, KOD, BCRX, and PGEN

Should you buy MiMedx Group stock or one of its competitors? MiMedx Group's main competitors and comparable companies include Ultragenyx Pharmaceutical (RARE), Nektar Therapeutics (NKTR), Kodiak Sciences (KOD), BioCryst Pharmaceuticals (BCRX), and Precigen (PGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MiMedx Group compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Ultragenyx Pharmaceutical currently has a consensus target price of $59.44, suggesting a potential upside of 132.11%. MiMedx Group has a consensus target price of $8.57, suggesting a potential upside of 90.48%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

MiMedx Group has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.75	-$575M	-$5.84	N/A
MiMedx Group	$418.63M	1.57	$48.58M	$0.04	112.50

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical had 15 more articles in the media than MiMedx Group. MarketBeat recorded 21 mentions for Ultragenyx Pharmaceutical and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.15 beat Ultragenyx Pharmaceutical's score of 1.07 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	10 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has a net margin of 1.76% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. MiMedx Group's return on equity of 12.09% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
MiMedx Group	1.76%	12.09%	9.22%

Summary

Ultragenyx Pharmaceutical beats MiMedx Group on 9 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Nektar Therapeutics?

MiMedx Group (NASDAQ:MDXG) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Nektar Therapeutics had 3 more articles in the media than MiMedx Group. MarketBeat recorded 9 mentions for Nektar Therapeutics and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.15 beat Nektar Therapeutics' score of 0.65 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

MiMedx Group presently has a consensus price target of $8.57, indicating a potential upside of 90.48%. Nektar Therapeutics has a consensus price target of $141.50, indicating a potential upside of 95.12%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

MiMedx Group has a net margin of 1.76% compared to Nektar Therapeutics' net margin of -287.84%. MiMedx Group's return on equity of 12.09% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

MiMedx Group has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.57	$48.58M	$0.04	112.50
Nektar Therapeutics	$55.23M	44.83	-$164.08M	-$6.70	N/A

Summary

MiMedx Group beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

MiMedx Group has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
MiMedx Group	$418.63M	1.57	$48.58M	$0.04	112.50

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 2.5% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Kodiak Sciences had 3 more articles in the media than MiMedx Group. MarketBeat recorded 9 mentions for Kodiak Sciences and 6 mentions for MiMedx Group. Kodiak Sciences' average media sentiment score of 1.29 beat MiMedx Group's score of 1.15 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences presently has a consensus price target of $48.14, suggesting a potential upside of 27.63%. MiMedx Group has a consensus price target of $8.57, suggesting a potential upside of 90.48%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of 1.76% compared to Kodiak Sciences' net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
MiMedx Group	1.76%	12.09%	9.22%

Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Summary

MiMedx Group beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks.

How does MiMedx Group compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

MiMedx Group has a net margin of 1.76% compared to BioCryst Pharmaceuticals' net margin of -40.90%. MiMedx Group's return on equity of 12.09% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
MiMedx Group	1.76%	12.09%	9.22%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

BioCryst Pharmaceuticals currently has a consensus price target of $20.60, indicating a potential upside of 109.78%. MiMedx Group has a consensus price target of $8.57, indicating a potential upside of 90.48%. Given BioCryst Pharmaceuticals' higher probable upside, research analysts plainly believe BioCryst Pharmaceuticals is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

BioCryst Pharmaceuticals has higher revenue and earnings than MiMedx Group. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.87	$263.86M	-$1.50	N/A
MiMedx Group	$418.63M	1.57	$48.58M	$0.04	112.50

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than MiMedx Group. MarketBeat recorded 12 mentions for BioCryst Pharmaceuticals and 6 mentions for MiMedx Group. BioCryst Pharmaceuticals' average media sentiment score of 1.39 beat MiMedx Group's score of 1.15 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioCryst Pharmaceuticals beats MiMedx Group on 10 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Precigen?

MiMedx Group (NASDAQ:MDXG) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

MiMedx Group has a net margin of 1.76% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Precigen	-183.98%	423.75%	84.39%

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MiMedx Group presently has a consensus price target of $8.57, indicating a potential upside of 90.48%. Precigen has a consensus price target of $14.50, indicating a potential upside of 108.63%. Given Precigen's stronger consensus rating and higher probable upside, analysts clearly believe Precigen is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Precigen had 10 more articles in the media than MiMedx Group. MarketBeat recorded 16 mentions for Precigen and 6 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.15 beat Precigen's score of 0.65 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.57	$48.58M	$0.04	112.50
Precigen	$9.68M	255.97	-$250.64M	-$1.04	N/A

MiMedx Group has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Summary

MiMedx Group beats Precigen on 9 of the 17 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$657.38M	$4.02B	$7.24B	$12.93B
Dividend Yield	N/A	3.60%	2.54%	10.96%
P/E Ratio	112.53	11.56	271.21	25.38
Price / Sales	1.57	1,346.04	623.95	92.16
Price / Cash	8.14	110.59	79.29	54.21
Price / Book	3.04	16.50	12.95	6.14
Net Income	$48.58M	-$22.76M	$3.46B	$347.93M
7 Day Performance	3.93%	-0.19%	-0.16%	-0.77%
1 Month Performance	3.21%	10.74%	7.32%	3.80%
1 Year Performance	-37.33%	53.31%	23.87%	14.69%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	3.1129 of 5 stars	$4.50 -0.2%	$8.57 +90.5%	-37.1%	$657.38M	$418.63M	112.53	870	Analyst Forecast
RARE Ultragenyx Pharmaceutical	3.5435 of 5 stars	$25.24 -3.4%	$57.82 +129.1%	-12.7%	$2.49B	$673M	N/A	1,371	Positive News Analyst Forecast
NKTR Nektar Therapeutics	2.3234 of 5 stars	$73.63 +1.3%	$150.00 +103.7%	+154.6%	$2.49B	$55.23M	N/A	220
KOD Kodiak Sciences	2.7857 of 5 stars	$39.66 -3.2%	$48.14 +21.4%	+318.8%	$2.48B	N/A	N/A	90	Positive News
BCRX BioCryst Pharmaceuticals	3.1327 of 5 stars	$9.60 -3.5%	$20.60 +114.7%	+15.8%	$2.45B	$874.84M	N/A	530	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. RARE, NKTR, KOD, BCRX, and PGEN

How does MiMedx Group compare to Ultragenyx Pharmaceutical?

Summary

How does MiMedx Group compare to Nektar Therapeutics?

Summary

How does MiMedx Group compare to Kodiak Sciences?

Summary

How does MiMedx Group compare to BioCryst Pharmaceuticals?

Summary

How does MiMedx Group compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. RARE, NKTR, KOD, BCRX, and PGEN

How does MiMedx Group compare to Ultragenyx Pharmaceutical?

Do analysts prefer RARE or MDXG?

Which has more risk & volatility, RARE or MDXG?

Which has preferable valuation and earnings, RARE or MDXG?

Do institutionals & insiders hold more shares of RARE or MDXG?

Does the media refer more to RARE or MDXG?

Is RARE or MDXG more profitable?

Summary

How does MiMedx Group compare to Nektar Therapeutics?

Do insiders & institutionals have more ownership in MDXG or NKTR?

Does the media prefer MDXG or NKTR?

Which has more volatility and risk, MDXG or NKTR?

Do analysts rate MDXG or NKTR?

Is MDXG or NKTR more profitable?

Which has higher valuation and earnings, MDXG or NKTR?

Summary

How does MiMedx Group compare to Kodiak Sciences?

Which has stronger earnings & valuation, KOD or MDXG?

Do institutionals and insiders hold more shares of KOD or MDXG?

Does the media refer more to KOD or MDXG?

Do analysts recommend KOD or MDXG?

Is KOD or MDXG more profitable?

Which has more volatility & risk, KOD or MDXG?

Summary

How does MiMedx Group compare to BioCryst Pharmaceuticals?

Is BCRX or MDXG more profitable?

Do insiders & institutionals believe in BCRX or MDXG?

Which has more volatility and risk, BCRX or MDXG?

Do analysts recommend BCRX or MDXG?

Which has stronger valuation and earnings, BCRX or MDXG?

Does the media favor BCRX or MDXG?

Summary

How does MiMedx Group compare to Precigen?

Is MDXG or PGEN more profitable?

Do institutionals and insiders believe in MDXG or PGEN?

Do analysts recommend MDXG or PGEN?

Does the media prefer MDXG or PGEN?

Which has preferable valuation & earnings, MDXG or PGEN?

Which has more volatility & risk, MDXG or PGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools